JP2017507931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507931A5 JP2017507931A5 JP2016550261A JP2016550261A JP2017507931A5 JP 2017507931 A5 JP2017507931 A5 JP 2017507931A5 JP 2016550261 A JP2016550261 A JP 2016550261A JP 2016550261 A JP2016550261 A JP 2016550261A JP 2017507931 A5 JP2017507931 A5 JP 2017507931A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- composition according
- agent
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020144077A JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2023126665A JP7767361B2 (ja) | 2014-02-05 | 2023-08-03 | がん及び感染症の治療方法並びに治療用組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936168P | 2014-02-05 | 2014-02-05 | |
| US61/936,168 | 2014-02-05 | ||
| PCT/US2015/014687 WO2015120198A1 (en) | 2014-02-05 | 2015-02-05 | Methods and compositions for treating cancer and infectious diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144077A Division JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017507931A JP2017507931A (ja) | 2017-03-23 |
| JP2017507931A5 true JP2017507931A5 (cg-RX-API-DMAC7.html) | 2018-03-08 |
Family
ID=53778458
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550261A Pending JP2017507931A (ja) | 2014-02-05 | 2015-02-05 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2020144077A Active JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2023126665A Active JP7767361B2 (ja) | 2014-02-05 | 2023-08-03 | がん及び感染症の治療方法並びに治療用組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144077A Active JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2023126665A Active JP7767361B2 (ja) | 2014-02-05 | 2023-08-03 | がん及び感染症の治療方法並びに治療用組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11213583B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3102233B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2017507931A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105979961B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2937035A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015120198A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| US8906374B2 (en) | 2010-04-20 | 2014-12-09 | Cedars-Sinai Medical Center | Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| EP3102233B1 (en) * | 2014-02-05 | 2025-12-17 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| EP3132802B1 (en) * | 2014-02-21 | 2020-06-17 | IDAC Theranostics, Inc. | Therapeutic agent for solid cancer |
| UY36032A (es) | 2014-03-14 | 2015-10-30 | Novartis Ag | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas |
| EP3126386A1 (en) | 2014-03-31 | 2017-02-08 | F. Hoffmann-La Roche AG | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
| US11168137B2 (en) | 2014-06-11 | 2021-11-09 | Idac Theranostics, Inc. | Method for reducing side effects of immune checkpoint control agent |
| CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
| EA201790834A1 (ru) | 2014-10-14 | 2018-01-31 | Новартис Аг | Молекулы антител к pd-l1 и их применение |
| WO2016090219A1 (en) * | 2014-12-05 | 2016-06-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bromodomain inhibitor as adjuvant in cancer immunotherapy |
| WO2016203025A1 (en) * | 2015-06-17 | 2016-12-22 | Curevac Ag | Vaccine composition |
| WO2017031363A2 (en) | 2015-08-18 | 2017-02-23 | Aspyrian Therapeutics, Inc. | Methods for manufacturing phthalocyanine dye conjugates and stable conjugates |
| ES2992591T3 (en) | 2015-08-18 | 2024-12-16 | Rakuten Medical Inc | Compositions, combinations and related methods for photoimmunotherapy |
| MY198560A (en) | 2015-10-02 | 2023-09-05 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| NZ749355A (en) | 2016-05-27 | 2023-04-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
| CN109963871A (zh) | 2016-08-05 | 2019-07-02 | 豪夫迈·罗氏有限公司 | 具有激动活性的多价及多表位抗体以及使用方法 |
| EP3496707A4 (en) * | 2016-08-09 | 2020-03-25 | Angimmune, LLC | Treatment of cancer using a combination of immunomodulation and check point inhibitors |
| TWI843168B (zh) | 2016-10-11 | 2024-05-21 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| US11407831B2 (en) * | 2017-10-30 | 2022-08-09 | Ube Industries, Ltd. | Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent |
| KR102721494B1 (ko) * | 2018-04-17 | 2024-10-24 | 국립암센터 | 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도 |
| CN113194967A (zh) * | 2018-09-27 | 2021-07-30 | 健诺西生物科学公司 | 治疗方法 |
| KR102300846B1 (ko) * | 2019-11-01 | 2021-09-09 | 서울대학교산학협력단 | 면역 활성 개선용 조성물 및 이의 방법 |
| CN114980919A (zh) * | 2019-11-18 | 2022-08-30 | 儿童医学中心公司 | 过度活化驻留树突状细胞的刺激物用于癌症免疫疗法 |
| JP2023513477A (ja) * | 2020-01-30 | 2023-03-31 | エーペックスイミューン セラピューティクス インコーポレイテッド | Ｐｌａ２ｇ２ｄアンタゴニストによる癌またはウイルス感染を処置するための方法および組成物 |
| CN115197320A (zh) | 2021-04-07 | 2022-10-18 | 中美冠科生物技术（太仓）有限公司 | 新型抗cd4抗体 |
| KR20250153210A (ko) * | 2023-02-06 | 2025-10-24 | 지엠피 바이오테크놀로지 리미티드 | 암을 위한 mtor 치료제 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| GB2302353B (en) | 1995-06-21 | 1998-11-11 | British Gas Plc | Method of filling an excavated opening |
| GB0217777D0 (en) | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
| WO2004045512A2 (en) | 2002-11-15 | 2004-06-03 | Genmab A/S | Human monoclonal antibodies against cd25 |
| EP2366717A3 (en) | 2004-10-29 | 2011-12-14 | University of Southern California | Combination Cancer Immunotherapy with Co-Stimulatory Molecules |
| US20090317407A1 (en) * | 2006-05-02 | 2009-12-24 | Lacelle Michael G | Augmentation of immune response to cancer vaccine |
| US20090311249A1 (en) | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
| JP2009541338A (ja) | 2006-06-19 | 2009-11-26 | ワイス | Ｉｌ−２２およびｉｌ−１７の調節方法 |
| EP2405270B1 (en) | 2006-06-30 | 2013-07-17 | Merck Sharp & Dohme Corp. | IGFBP2-Biomarker |
| WO2010027423A2 (en) * | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| EP2374883B1 (en) * | 2008-12-26 | 2016-08-10 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd4 antibody |
| CN102281761A (zh) | 2009-01-14 | 2011-12-14 | 健康研究股份有限公司 | 用于增强免疫应答的方法和含有mTOR抑制剂的组合物 |
| WO2010124498A1 (en) * | 2009-04-30 | 2010-11-04 | Beijing Cellonis Biotechnology Co., Ltd | A resistance-screened tumor stem cell, its antigen composition, an anti-tumor dendritic cell loading with said antigens, their preparation methods, uses and kits thereof as well as a dendritic cell vaccine |
| US8993524B2 (en) * | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US8906374B2 (en) | 2010-04-20 | 2014-12-09 | Cedars-Sinai Medical Center | Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors |
| WO2011139738A2 (en) * | 2010-04-28 | 2011-11-10 | Tenx Biopharma, Inc. | Therapies using zanolimumab to enhance the immune response |
| US9308253B2 (en) * | 2011-09-19 | 2016-04-12 | The Johns Hopkins University | Cancer immunotherapy |
| EP3102233B1 (en) | 2014-02-05 | 2025-12-17 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| CN106413751A (zh) * | 2014-05-21 | 2017-02-15 | 辉瑞大药厂 | 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合 |
| JP6274542B2 (ja) | 2014-12-02 | 2018-02-07 | 国立大学法人 東京大学 | 抗ｃｄ４抗体を有効成分とする抗がん剤の治療効果を判定する方法 |
-
2015
- 2015-02-05 EP EP15747022.0A patent/EP3102233B1/en active Active
- 2015-02-05 US US15/116,485 patent/US11213583B2/en active Active
- 2015-02-05 CN CN201580007415.4A patent/CN105979961B/zh active Active
- 2015-02-05 JP JP2016550261A patent/JP2017507931A/ja active Pending
- 2015-02-05 WO PCT/US2015/014687 patent/WO2015120198A1/en not_active Ceased
- 2015-02-05 CA CA2937035A patent/CA2937035A1/en active Pending
-
2020
- 2020-08-28 JP JP2020144077A patent/JP7328187B2/ja active Active
-
2021
- 2021-11-22 US US17/533,065 patent/US20220152198A1/en active Pending
-
2023
- 2023-08-03 JP JP2023126665A patent/JP7767361B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507931A5 (cg-RX-API-DMAC7.html) | ||
| JP2023133525A5 (cg-RX-API-DMAC7.html) | ||
| US20250262318A1 (en) | Methods and pharmaceutical composition for the treatment of cancer | |
| US20230181605A1 (en) | Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity | |
| JP2017501167A5 (cg-RX-API-DMAC7.html) | ||
| US12377094B2 (en) | Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapies | |
| RU2017121096A (ru) | Комбинированная терапия, включающая применение ох40-связывающих агонистов и антагонистов связывания оси pd-1 | |
| JP2017537090A5 (cg-RX-API-DMAC7.html) | ||
| KR20180105685A (ko) | 투카레솔 또는 이의 유사체를 함유하는 조성물 | |
| KR20170137717A (ko) | 암의 치료를 위한 방법, 조성물, 및 키트 | |
| BRPI0717688A2 (pt) | mÉtodos para tratar neoplasma e mÉtodos para tratar neoplasma de plasmàcitos | |
| JP2019503387A5 (cg-RX-API-DMAC7.html) | ||
| US20220265823A1 (en) | Uses of myostatin antagonists, combinations containing them and uses thereof | |
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| JP2024016209A (ja) | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ | |
| WO2023240082A2 (en) | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer | |
| JP2023501209A (ja) | 白血病またはリンパ腫の治療のためのレナリドミドと組み合わせた抗ｃｄ１９療法 | |
| US20220025061A1 (en) | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist | |
| CN102935228B (zh) | 用于肿瘤治疗的试剂、其用途及方法 | |
| CN113573707A (zh) | 用于治疗癌症的组合产品 | |
| US20250034255A1 (en) | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer | |
| EP3008089A1 (en) | Combination of cd37 antibodies with chlorambucil | |
| WO2018227280A1 (en) | Therapeutic combinations comprising eosinophil-depleting antibodies and uses thereof | |
| WO2025190251A1 (zh) | 抗trop2抗体药物偶联物和pd-1拮抗剂联合治疗实体瘤的用途 | |
| WO2025021587A1 (en) | Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof |